img

Company

  • icon
    img

    Basgenbio proposes value beyond health through Biological Big data.

    Basgenbio leads innovative disease prevention method and drug development
    using AI technology implemented with vast amount of data from Global Biobank as well as K-Biobank.

    Key Personnel

    Management Team
    img
    Il-Tae Jang CEO
    Chief executive officer
    • Medical Doctor
    • Chairman of Nanoori Medical Foundation
    Understanding the root causes of diseases through immense medical data and genetic information stored in blood.

    Basgenbio aims to take a leading role in the fields of preventive and precision medicine by leveraging AI and Biological Big data. The goal is to pioneer in new healthcare market by combining genomic and medical data, thus extending the lifespan and improving quality of life of humanity. To achieve this, Basgenbio continuously develops and enhances the AI algorithms and conducts Big data analysis to find the causes and treatments of various diseases. We are dedicated to enhancing healthcare and pursuit happiness through the fusion of AI technology and biomedicine.

    img
    Ho Kim CEO
    Genetic epidemiology R&D
    Extending healthy human life based on clinical genomic cohort data.

    By developing appropriate therapeutic drugs through biomarker discovery, Basgenbio focuses on predicting the occurrence and progression of diseases over time. We explore the potential of future medicine based on genomic cohort data and proprietary technology, aiming to lead an active and creative medical approaches in response to diseases.

    img
    Haeng Seok Yoo Vice President
    Chief Financial Officer
    Establishing transparent financial management and accurate investment strategies.

    Basgenbio has secured genetic cohort data that is not easily obtainable by anyone in the era of data competition. Although there are still many problems to be solved to use this valuable data efficiently, Basgenbio is highly commended for their direction and growth.

    We promise to make active efforts to extend the 'healthy lifespan' of human.

    img
    Jung-Eun Kim Head of AI Drug Development Division
    Head of division, AI Drug Development Division
    Broadening the possibilities of future medicine by analyzing genomic and epidemiological data.

    Basgenbio strives to derive meaningful results using human genomic and epidemiological data as in silico analysis specialists. We value communication and collaboration with our clients and flexibly adapt to various situations. As one of the leaders in drug development, drug efficacy simulation, and biomarker discovery, we expand the possibilities of future medicine with top-tier data and technology.

    Advisory Board
    img
    Eun-Hee Ha M.D., Ph.D.
    Outside Director / Medical / Environmental Advisory Board
    Based on genomic cohort data, extending healthy human life.

    Professor Eun-hee Ha, after obtaining her doctorate in Preventive Medicine and 28 years of tenure at Ewha Womans University, conducted continuous Basic and Policy Research based on her academic interests in Environmental Epidemiology and Medicine, and Environmental Health Policy.

    In particular, in 2015, she consolidated her research capabilities and received recognition as a leading expert in the field of Environmental Medicine, establishing the National Children’s Environmental Health Birth Cohort Support Center and laying the foundation for the Korean nationwide birth cohort.

    She has published over 160 papers in international SCI journals, received the Presidential Commendation for Environmental Conservation in 2009, the National Medal in 2018 from the Korea Ministry of Environment. She also received the Ewha Academic Award in 2019 and is currently serving as the 26th Dean of the College of Medicine at Ewha Womans University.

    img
    Won-il Jeong Ph.D.
    Statistics Advisory Board

    Professor Won-il Jeong obtained a master's degree in Natural Science at Seoul National University followed by a Ph.D. in Medical Statistics at University of North Carolina in the United States. He later worked as a Research Fellow at Harvard University.

    Subsequently, he served as an Assistant Professor at the Department of Information Statistics and Actuarial Science at Soongsil University, leading various research projects in medical and genetic statistics. He is also actively involved at the Korean Statistical Society (KSS) and the Korea Genome Organization (KOGO).

    To this day, he has led numerous research projects and played a leading role in genomics-based statistical research.